CD86 and type 1 diabetes mellitus: In-vitro IL-15 treatment of T1D donor B cells led to elevated levels of CD226+ B cells (Fig. 5b), along with increased expression of CD69, CD86, TNF-α, and IL-6 (Fig. 5c–f) by CD226+ B cells.